May 30, 2025

Explainable artificial intelligence increases the accuracy and endurance of dermatologists in melanoma diagnosis

Explainable artificial intelligence increases the accuracy and endurance of dermatologists in melanoma diagnosis

Scientists at the German Cancer Research Center (DKFZ) have shown in an international eye-tracking study that dermatologists not only improve their diagnostic accuracy by using explainable artificial intelligence, but also show significantly less fatigue when assessing challenging cases. The researchers were able to demonstrate this by measuring a reduction in cognitive stress indicators.

Bastian Schilling, Director at the Dermatology Clinic of Frankfurt University, was one of the dermatologists participating in the current study.
(C) private

In a two-phase study, 76 dermatologists each assessed 16 images (melanomas and benign moles, known as nevi) taken with a dermatoscope, an illuminated magnifying glass, first using standard AI and then with an explainable AI solution. Explainable AI, or XAI for short, combines AI predictions with textual and image-based explanations based on established dermatoscopic features. Eye-tracking measurements were used to record how long and how intensively the participants looked at certain image regions and explanations.

Eye tracking as an objectification method

Analysis of gaze patterns showed that difficult cases were associated with an increased number of fixations – an objective indicator of cognitive effort. In the XAI phase, this effort decreased in challenging cases compared to standard AI, indicating a relieving effect of the explanations provided.

“Our results show that explainable AI not only increases diagnostic confidence, but can also support endurance in difficult cases in clinical practice,” explains Titus J. Brinker, senior author of the current study. “Especially with a high caseload and complex lesions, explainable artificial intelligence can help prevent fatigue and thus minimize potential sources of error.”

Follow-up studies are planned to investigate the long-term impact on workload and diagnostic quality in real-world clinical settings.


Chanda, T., Haggenmueller, S., Bucher, TC. et al. Dermatologist-like explainable AI enhances melanoma diagnosis accuracy: eye-tracking study.
Nature Communications, 2025, https://doi.org/10.1038/s41467-025-59532-5

Our latest News

discover more
European Biotech Act: bioRN brings Industry and Policymakers together

European Biotech Act: bioRN brings Industry and Policymakers together

How can Europe strengthen its global competitiveness in biotechnology? Heidelberg, July 7th: This question was at the heart of a high-level roundtable hosted by the bioRN Life Science Cluster with Member of the European Parliament Hildegard Bentele. Representatives from Ascendis Pharma, BD, PROGEN, Novaliq, BASF Agricultural Solutions, PEPperPRINT, Evotec and Isenbruck Bösl Hörschler joined the […]

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

NORTH CHICAGO, Ill., July 6, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 […]

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

It should be biofunctional – that is, it should replicate the natural cellular environment as closely as possible – and it should be printable: bioink. Achieving both of these properties at the same time is an enormous challenge that conventional biomaterials often fail to meet. Together with two partner companies, researchers at the NMI have now taken an important […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp